Seung Hun Lee1, Jong Woo Kim2, Hyun-Ki Yoon2, Jung-Min Koh1, Chan Soo Shin3, Sang Wan Kim3,4, Jung Hee Kim3. 1. Division of Endocrinology and Metabolism, Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. 2. Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. 3. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. 4. Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea.
We appreciate the insightful comments from Dr. Singhania regarding our recent publication. We reported that patients with hypokalemia, a plasma aldosterone concentration >30.0 ng/dL, and unilateral lesions on computed tomography were at high risk of unilateral primary aldosteronism regardless of age [1]. We would like to respond as follows.First, Dr. Singhania pointed out that the importance of hypokalemia in diagnosing primary aldosteronism—particularly unilateral adenoma—was overemphasized. We agree that the prevalence of hypokalemia was relatively low in patients with primary aldosteronism. However, the presence of hypokalemia might reflect the disease severity, and a recent clinical guideline suggested that the presence of hypokalemia enables bypassing confirmatory testing for primary aldosteronism [2]. Our study found that hypokalemia alone was not a significant predictor, but that it became a more significant predictor together with other criteria. Moreover, previous studies have suggested that hypokalemia is a significant predictor of unilateral primary aldosteronism [3-5].Second, Dr. Singhania pointed out that confirmatory testing can be skipped in the clinical setting of hypertension, spontaneous hypokalemia with a plasma aldosterone concentration >555 pmol/L (>20 ng/dL), and plasma renin activity <1 ng/mL/hr (or a plasma renin concentration below the lower limit of the reference range). We also agree that confirmatory testing is not necessary for patients with primary aldosteronism, according to the previously-mentioned guideline [2]. However, our study included patients from 2000 to 2018, which included the period before the guideline was published. Thus, our two centers consistently conducted confirmatory tests in patients with primary aldosteronism.We deeply appreciate Dr. Singhania’s valuable comments, which enriched the understanding of our article.
Authors: John W Funder; Robert M Carey; Franco Mantero; M Hassan Murad; Martin Reincke; Hirotaka Shibata; Michael Stowasser; William F Young Journal: J Clin Endocrinol Metab Date: 2016-03-02 Impact factor: 5.958
Authors: Seung Hun Lee; Jong Woo Kim; Hyun-Ki Yoon; Jung-Min Koh; Chan Soo Shin; Sang Wan Kim; Jung Hee Kim Journal: Endocrinol Metab (Seoul) Date: 2021-03-31